Medichem, partners of CataloniaBio & HealthTech and supplier to the pharmaceutical industry, is expanding its production in Spain and opening new markets in Brazil. With an investment of 16.5 million euros, the company will establish its fourth production floor in the Technology Park of Asturias. It has also obtained certification from the Brazilian Health Regulatory Agency (Anvisa) to sell active ingredients and medicines on the market. 

Mitelos, partner of CataloniaBio & HealthTech, is the leading manufacturer of medical devices. Today it announces the renewal of the ISO 13485:2016 certification. This certification demonstrates Mitelos' commitment to providing high quality medical devices that meet the rigorous standards set by the International Organization for Standardization (ISO). 

The Hospital Clínic Barcelona has successfully performed the first surgeries with Bitrack, the surgical robot created by the Catalan company, Rob Surgical. The first surgeries were three radical nephrectomies and all three surgeries were performed satisfactorily, and, after a 30-day follow-up, no adverse events were observed as a result of the use of the Bitrack system.

Abzu, the Danish / Spanish startup that has introduced new methods and technology to drive discoveries in life science research, wins the Best HealthTech at the 2023 Nordic Startup Awards. The Best HealthTech award recognizes a startup with innovative and impactful technology solutions with a quantifiable positive impact on health and healthcare outcomes.

The funding raised by the companies that form part of the PCB Community, in transactions identified in 2022, reached €142M, an absolute record, of which €85M (58%) came from private capital. The Barcelona Science Park (PCB) comprises more than 125 entities, including the CataloniaBio & HealthTech offices and a large number of partners.

Miquel Vila Perelló (Barcelona, 1977) has a PhD in Chemistry (UB) and is a co-founder of SpliceBio, a biotech company that develops gene therapies for rare disorders for which there is no cure yet. The Bioèxit 2022 award is in recognition of the Series A €50M finance round, led jointly by UCB Ventures (Belgium) and Ysios Capital, with the participation of a powerful international syndicate. A spinoff of Princeton University, it was set up and established in Barcelona in 2012. 

It is a path that poses a special challenge for the limited resources available to biotech start-ups. For this reason, CataloniaBio & HealthTech brought together five experts from member companies, with knowledge and experience in different phases of the pharmaceutical development process, to share lessons learned in the usual Lessons Learned format. The session took place at the Barcelona Science Park.

Ship2B Ventures, a member of CataloniaBio & HealthTech, is launching a €30 million fund to invest in European companies in the field of paediatrics. The new fund is called Montana Impact Fund and plans to invest in between 16 and 18 companies in the early stages of research. 

MiMARK Diagnostics, member of CataloniaBio & HealthTech , specialises in the development of innovative solutions for gynaecological diagnostics. The Vall d’Hebron Research Institute (VHRI) spin-off has raised €1m to accelerate the development of its in vitro diagnostic test for endometrial cancer WomEC and initiate the development plan for its diagnostic test for endometriosis.

Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, announced the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD).

Clinicas Mi and HumanITcare have signed a collaboration agreement to accompany cancer patients throughout their treatment, from any location, 24 hours a day, 365 days a year.

Global biopharmaceutical company Almirall, a member of CataloniaBio &HealthTech, has entered into a research collaboration with the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence. The partnership aims to develop and characterize novel preclinical models that will help identify new treatments for non-melanoma skin cancer (NMSC).

Rob Surgical, dedicated to the design and development of new robotic systems, has recently received authorisation to conduct FIH clinical trials. This new milestone brings the medical robotics technology company closer to its founding purpose: to universalise high-precision surgery and bring its benefits to hospitals, surgeons and patients worldwide.

CataloniaBio & HealthTech took part in the initiative as a participant in the programme's discussion areas, specifically in the session focused on regulatory issues, market access, funding, and talent. CataloniaBio & HealthTech member companies and institutions also participated, including Grifols, SpliceBio, invivo capital, the Blood and Tissue Bank, Leitat, IBEC, Vall d'Hebron and Creatio (UB).

Oniria Therapeutics ha tancat una ronda d'inversió llavor per un total d'1,28 milions d'euros, que permetrà avançar en el desenvolupament d'ONR-001, un fàrmac first-in-class per eliminar les cèl·lules tumorals persistents alstractaments convencionals. Les cèl·lules persistents o latents són les responsables del 90% de les morts per càncer ja que originen nous tumors que causen recaigudes i metàstasi.

The VISOR EEG project, led by mjn-neuro, is developing an out-of-hospital and portable system for prolonged EEG recordings in patients with epilepsy and other neurological disorders. The main objective is the design and development of a system consisting of three devices capable of recording a patient's brain activity in an easy and quick way to install and configure.

D-Sight, a spin-off of the Vall d'Hebron Research Institute (VHIR), and CataloniaBio & HealthTech member, has received an investment of one million euros from the venture capital fund Clave Capital to develop new innovative therapeutic strategies for the treatment of diabetic retinopathy and other neurodegenerative diseases of the retina, such as glaucoma. This operation is the fund’s first investment in Catalonia.

L’Hospital Parc Taulí ha creat una nova unitat al servei d’Urgències: la Unitat Assistencial de Resolució Avançada (ARA), constituïda per infermeres i que compta amb el suport d’un software d’intel·ligència artificial, desenvolupat per Mediktor. Amb aquesta nova eina, l’equip d’infermeria orienta i tracta pacients amb patologies de baixa complexitat i elevada incidència; disminuint, significativament, els temps d’espera sense perdre la qualitat i seguretat de l’assistència sanitària.

SocialDiabetes and Novo Nordisk are bringing together knowledge and digital health solutions to help people with diabetes and the healthcare professionals who treat them to optimise glucose control. And there is no doubt that diabetes is one of the diseases that requires those who suffer from it to be more involved and make more decisions daily to control their diabetes.

IBEC’s Core Facilities and nine of its research groups have undergone the “green laboratory” certification process granted by the My Green Lab organization, all awarded with the highest levels of certification.